Paper on the Phase 0-trial of AB001 accepted for publication
Our research group is pleased to announce that we have had results from a phase 0-trial on AB001, a novel PSMA-targeted radioligand labeled with the α-emitter 212Pb, accepted for publication in the Journal of Nuclear Medicine. The study explores the use of γ-camera imaging to assess biodistribution and uptake of AB001 in patients with metastatic castration-resistant prostate cancer (mCRPC).
The study was conducted at Oslo University Hospital, and sponsored by ARTBIO. The publication was a result of an excellent multidisiplinary collaboration, and especially the joint first authors Kjetil Berner (Department of Oncology) and Eivor Hernes (Department of Nuclear Medicine), together with Monika Kvassheim and senior author Caroline Stokke (our group) played key roles. Group members Simen Rykkje Grønningsæter and Lars Tore Gyland Mikalsen also gave valuable contributions. The work showed that AB001 can be safely administered and imaged at a microdose of only 10 MBq, and successfully demonstrated metastatic targeting. The findings offer valuable insights into the biodistribution and clearance of 212Pb-labeled radioligands, paving the way for further clinical development in targeted alpha therapy.